BioMedWire Stocks

20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS

Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid. 

Advisers to the HHS Secretary ordered CMS officials to release private data, including names, immigration status, social security numbers, addresses, as well as claims data by those enrollees in several jurisdictions, such as Washington State, Illinois, Washington, D.C., and California to the Department of Homeland Security (DHS). The states included in the data sharing request were selected because those states allow immigrants who haven’t regularized their stay to access Medicaid funded by revenue generated locally within the state. 

While announcing the filing of the lawsuit, Bonta said the federal administration had violated longstanding privacy laws protecting health information, such as HIPAA. The private health data shared can enable deportation officials to identify and locate individuals that are in the country illegally, and then deport them. 

Available information suggests that a plan was set in motion back in May to give federal authorities access to private Medicaid data from states that allow undocumented immigrants to access state government-funded Medicaid. At the time, CMS revealed that it would be conducting a review to ascertain that those states weren’t using federal funds to provide Medicaid to illegal immigrants. 

Consequently, CMS asked those states to share their Medicaid data for the review. Hardly a month later, HHS asked CMS to share that data with DHS. Despite back and forth email communication in which CMS officials explained why it would be illegal to share such information, HHS wrote to CMS ordering them to release the data by 5:30 ET on the very day (June 10) that directive was sent. 

HHS insists that its actions are within the law and that it is executing its mandate to ensure Medicaid benefits go to citizens and not non-citizens. The agency doesn’t explain how giving that information to DHS helps HHS to perform its role. 

It is against this backdrop that 20 states are suing over the matter. There is concern that the federal administration is willing to flout existing laws in order to attain its objectives, such as conducting mass deportations. 

The possibility that the private health data of their policyholders could one day be shared in violation of all laws protecting the privacy of this data must be causing firms like Astiva Health plenty of concern because such violations are unprecedented. 

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals…

8 hours ago

Lund University Researchers Discover Why Leukemia Cells Evade the Immune System

While immunotherapy has scored a significant level of success in treating many types of cancer,…

8 hours ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

9 hours ago

Why Health Insurance Credits Led to the Federal Government Shutdown

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open…

4 days ago

Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare…

5 days ago

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients…

6 days ago